Oncology

Referrals to dietitians may help in the management of TEAEs affecting taste and smell, as well as fatigue in patients undergoing cancer treatment.

Results from a phase 2 trial showed a 1-year local control rate of 93.1% with SABR in patients with solid tumors who have uncomplicated bone metastases.

Updates on treatments like vusolimogene oderparepvec for advanced melanoma, and novel therapies have been provided by the FDA.

The denosumab biosimilars have been approved based on review of a comprehensive data package that showed no meaningful differences vs the already approved agents.

Boris M. Kiselev, MD, discusses the role of psycho-oncology in comprehensive cancer care, addressing barriers and offering a vision for the field’s future.

An oncologist’s passion for breast surgery, novel cancer vaccines in gastrointestinal cancers, and emerging actionable biomarkers for lung cancer were all covered in August.

Declan Walsh, MD, highlighted how the supportive and palliative care space has evolved since he first began working in the field.

Being proactive and quickly identifying when a patient may need the supportive care team is the best way to integrate this field into whole-person care.

The Chemo Mouthpiece had favorable outcomes when used during and after treatment with chemotherapy among a range of patients with various types of cancer.

A survey found that patients believed dermatologic AEs were more prevalent with anti-cancer therapies than what has been reported.

The EC decision is based on phase 3 DeFi trial results, in which nirogacestat met the primary end point of PFS in patients with progressing desmoid tumors.

Geraldine O’Sullivan Coyne, MD, PhD, MRCPI, described the excitement of seeing novel molecules such as antibody-drug conjugates become more prominent.

Ronald Bleday, MD, credits a chronic pain clinic for consulting patients who may be at a greater risk for prolonged opioid use following surgery.

An update of phase 1 data from the CTMX-2051-101 study is expected to be available by the first quarter of 2026.

Immunocompromised individuals face ongoing COVID-19 risks despite vaccination, highlighting the need for tailored public health strategies and innovative therapies.

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, shares how a new position presents a “good opportunity” to improve community-based clinical trial access.

The development of nonnarcotic pain medication after GI surgery may help relieve chronic pain without the risk of opioid dependence.

Ronald Bleday, MD, stated that before standardizing a stepwise approach to treating surgical pain, providers might have overtreated patients with opioids.

Conducting trials safely within a community setting lies at the heart of a successful collaboration between Northwell Health and START.

The expertise of START's network may streamline the availability of clinical trial enrollment and novel treatment options among patients with cancer.

A new START center in New York may give patients with advanced malignancies an opportunity to access novel therapies in the community setting.

START is the largest early-phase oncology network in the community-based setting, according to Geraldine O’Sullivan Coyne, MD, PhD, MRCPI.

The 2025 National ICE-T Symposium gave oncology experts an opportunity to share ideas regarding the administration of cellular therapies.

The intravenous formulation of tocilizumab-anoh for CRS is expected to launch in the US on August 31, 2025.

Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.